Phillips-Medisize today announced a doubling of production for an undisclosed fast-growing medical customer with a take-home diagnostic kit for cancer detection – with benefits for the plant that Phillips-Medisize’s parent Molex runs in Little Rock, Ark.
Phillips-Medisize, which is based in Hudson, Wis., did not disclose the identity of the customer, which it described as a leader in consumable diagnostics cancer testing.
The company in the past, though, has touted work it has done for Madison, Wis.–based Exact Sciences (Nasdaq: EXAS), maker of the take-home Cologuard colon cancer test. Cologuard test volume more than doubled to 571,000 tests in 2017.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.